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ABSTRACT
S100A2 is generally found expressed in the epider-
mis and was recently shown to play a crucial role in
the differentiation of keratinocytes. Also known as
CaN19, S100A2 was identified as a potential tumor
suppressor. Expression of S100A2 is upregulated
by p53. The proteins p63 and p73 are related to p53
and are expressed as several splice variants with
partially overlapping tasks but also functions differ-
ent from p53. It had been shown that p63 proteins
with mutations in their DNA-binding domain cause
severe phenotypes in man as autosomal dominantly
inherited disease including EEC, AEC, SHFM, LMS
and ADULT syndromes. Here we show that S100A2
is a transcriptional target of p63/p73 family mem-
bers, particularly the p63 splice variant TAp63c. The
regulation is mediated by a novel transcriptional
element in the S100A2 promoter which is bound by
TAp63c but not by p53. Mutant p63 proteins derived
from EEC and ADULT syndrome patients cannot
activateS100A2transcriptionwhereasSHFM-related
mutants still can stimulate the S100A2 promoter.
Consistent with a function in tumor suppression
S100A2 expression is stimulated upon DNA
damage. After doxorubicin treatment p63c proteins
arerecruitedtotheS100A2promoterinvivo.Thismay
indicate a function of the p63-dependent S100A2
regulation in tumor suppression.
INTRODUCTION
S100A2 was ﬁrst isolated from bovine lung tissue (1) and
is generally found expressed in the epidermis (2). Recently,
S100A2 was shown to play a crucial role during diﬀer-
entiation when its expression silenced by siRNA-mediated
mRNA knockdown resulted in decreased expression of
two keratinocyte diﬀerentiation markers (3). In contrast to
other S100 family members, S100A2 is located in the cell
nucleus (4,5) and is involved in keratinocyte response to
oxidative stress (6).
S100A2 is a member of the S100 family representing the
largest family within the EF-hand proteins. These proteins
are characterized by two distinct EF-hand motifs (7)
ﬂanking a central hinge region and act as Ca
2+ signaling
or Ca
2+ buﬀering proteins. In addition to Ca
2+ many
S100 family members display high aﬃnity also towards
Zn
2+ and Cu
2+ ions. The cDNA of S100A2 codes for
a 10.7-kDa protein which can form homodimers in
living cells (8) with aﬃnity to Ca
2+ and Zn
2+ ions (9).
Dimerization of S100 proteins appears to be important for
their biological function.
Members of the S100 family show a large diversity in
structure and function. They are involved in the regulation
of contraction, motility, cell growth, diﬀerentiation, cell
cycle progression, transcription and secretion. In contrast
to other EF-hand proteins, S100 proteins have so far been
found only in vertebrates and consequently form a
phylogenetically young group (10). Genes of most group
members are clustered in region 1q21 of human chromo-
some 1 which is known as epidermal diﬀerentiation
complex EDC (11). An analogous cluster is found on
chromosome 3 in mice. Usually the highly conserved gene
structure consists of three exons of which the ﬁrst exon is
noncoding. Furthermore, S100 proteins are expressed in a
cell and tissue-speciﬁc manner (12) implying that the
relatively large number of family members is not due to
redundancy (13).
Interestingly, S100A2—then named CaN19—was iden-
tiﬁed as a potential tumor suppressor gene by diﬀerential
expression in normal versus tumor-derived human mam-
mary epithelial cells (14). It was shown that S100A2
expression is markedly downregulated in several tumor
tissues (15–18). Methylation of the promoter mediates
S100A2 repression during breast cancer progression (19).
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p53 activates transcription of S100A2 (20). In addition,
S100A2 overexpression was found in gastric cancer (21),
ovarian cancer (22), lymphoma (23), head and neck
squamous cell carcinoma (24,25) and early-stage nonsmall
cell lung cancer (26). It was concluded that overexpression
of S100A2 may be an early tumorigenic event (21).
Another ﬁnding is that S100A2 modulates transcriptional
activity of p53 due to protein-protein interaction (27).
Recently it was shown that S100A2 could exert its
antitumor activity by repression of cyclooxygenase-2
expression (28).
Many biological processes like apoptosis and develop-
ment are critically regulated by members of the p53
family (29). p63 and p73 are a group of proteins that, like
p53, are transcription factors which activate target genes
through sequence-speciﬁc DNA binding (30–33). The high
level of amino acid sequence similarity within the
p53 family, particularly in the DNA-binding domain,
allows transactivation of common target genes. However,
members of the p53 family are not entirely functionally
redundant. While p53 is known as a classical tumor
suppressor, p63 seems to be capable of enforcing some
of the tumor suppressive mechanisms that p53 also
mediates (34). Furthermore, p63 plays an important role
in development. Mutations in the p63 DNA-binding
domain cause severe phenotypes in man as autosomal
dominantly inherited syndromes. This family of disorders
includes the EEC, AEC, SHFM, LMS and ADULT
syndromes. They are characterized by combination
of ectrodactyly, ectodermal dysplasia and facial clefting
(35–41). Recently, it was shown that p63 is able to bind
DNA elements which diﬀer from classical p53 consensus
(42,43). This implies that p53 and p63 can regulate
diﬀerent target genes.
Here we identify S100A2 as a novel transcriptional
target of the p63 isoform TAp63g. We show that mutants
of p63 which are responsible for the human EEC
syndrome fail to activate S100A2 transcription. In
addition, we ﬁnd that recruitment of p63g proteins to
the S100A2 promoter correlates with increased expression
of S100A2 following DNA damage.
MATERIALS AND METHODS
Cellculture, transfections and luciferase assays
SaOS-2 cells obtained from DSMZ (Braunschweig,
Germany) were cultured and transfected in 24-well
plates as described previously (44). DLD-1 cells stably
transfected with various p53 family-expressing plasmids
were cultured as described previously (44). DLD-1 cells
express only inactive mutant p53 protein (45) and display
a single nucleotide exchange in one p63 allele resulting in a
replacement of proline at position 279 in the TA p63
protein by histidine (46). The p73 gene in DLD-1 cells is
wild type (47).
Transient transfections using expression plasmids for
wild-type and mutant p53 family members (25ng) were
carried out according to the manufacturer’s instructions
using Fugene 6 (Roche, Mannheim, Germany) with 400ng
of the plasmid carrying the human S100A2 promoter and
25ng pRL-null vector (Promega, Mannheim, Germany)
per assay. The total amount of transfected DNA was held
constant. Luciferase assays were carried out as reported
earlier (48).
HepG2 and p53-negative Hep3B cells (49) were also
obtained from DSMZ and cultured as described (46).
As a DNA-damaging agent, doxorubicin was employed at
0.2ng/ml.
RNA extraction and real-time RT–PCR
Extraction of total RNA was performed employing the
RNeasy Protect Mini Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. Cells carry-
ing p53 family transgenes used for RNA preparations
were described earlier (44). Real-time RT–PCR mRNA
quantiﬁcation including calculations have been described
(50–52). Speciﬁc primers for human S100A2 50-GCG
ACA AGT TCA AGC TGA GT-30;5 0-CAC CTG CTG
GTC ACT GTT CT-30 (GenBank accession number
NM_005978) were used at 1mM on 50ng total RNA
template in the QuantiTect SYBR Green RT–PCR mix
(Qiagen, Hilden, Germany) employing a LightCycler
instrument (Roche).
Generation ofpolyclonal antibodies raised against
human S100A2
Full-length cDNA of S100A2 prepared from human blood
RNA where ampliﬁed using the primer 50-AAA CCA
TGG GCA GTT CTC TGG AGC AG 30 and 50-TTT
CTC GAG GGG TCG GTC TGG GCA GC-30. The
fragment was cloned into the NcoI/XhoI site of the
pTriEx-2 expression vector (Novagen, Madison, WI,
USA). The plasmid was used to transform Escherichia
coli BL21 cells. Cells were grown to a density of OD600nm
of 0.5 and expression of recombinant protein was induced
by adding 1mM isopropyl thio-b-D-galactopyranoside
(IPTG) to the culture for 4h. Cells were harvested by
centrifugation and cell lysates were used for Ni–His-
aﬃnity chromatography puriﬁcation. The eluate was
further puriﬁed using preparative SDS–PAGE. Bands
carrying S100A2 were cut out from the gel, ground in a
mortar in liquid nitrogen and suspended in PBS. For
immunization the antigen suspension was mixed with
an equal volume of the adjuvant TiterMax Gold
(CytRx Corporation, Los Angeles, CA, USA) and injected
subcutaneously into the neck area of a rabbit. In intervals
of 4 weeks antibody quality was tested by using decreasing
amounts of recombinant protein in western blot analyses.
Antiserum obtained after ﬁve immunizations was used for
western blot analysis.
Western blot analysis
Western blots were prepared essentially as previously
described (50). The polyclonal rabbit anti-human S100A2
serum was used in a 1:100 dilution. The blot was stripped
and reprobed with a 1:5000 dilution of the mouse
monoclonal anti-b-actin antibody (clone AC-15, Sigma,
Taufkirchen, Germany). The induction of p53 was
detected with the monoclonal mouse antibody DO-1
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whereas the induction of TAp63g was detected using the
mouse monoclonal anti-p63 antibody (clone 4A4; sc-8431
Santa Cruz Biotechnology, Santa Cruz, CA, USA) with
a 1:250 dilution.
Cloning and mutation ofhuman S100A2 promoter
and p63 expression constructs
The wild-type human S100A2-promoter ﬁreﬂy-luciferase
construct S100A2 short (20) was kindly provided by
Dr Beat W. Scha ¨ fer (University of Zurich, Switzerland).
However, most experiments were performed with a newly
created longer promoter construct. To this end, the ﬁrst
intron of S100A2 was ampliﬁed using the primers 50-TTT
GGT ACC GCC CCA GGT TGC TTC TCT C-30 and
50-TTT AGA TCT TGG ATC TGT GGC TGC AGA
G-30. This fragment was cloned into the KpnI/BgIII sites
of pGI3 basic vector (Promega, Mannheim, Germany).
In order to obtain the S100A2 long luciferase construct
the intron 1 fragment was cut out by SﬁI/BgIII and
inserted into the S100A2 short promoter in pGI3 that had
been linearized by SﬁI/HindIII digestion (GenBank
accession number EU036993). Promoter mutants were
created by PCR-based targeted mutagenesis on the basis
of S100A2 long employing the primers site1-50mut-fwd,
50-GGA TAG AGG GTG CAG GCA TGT GTG GGT
CGA TTC TGA AC-30; site1-30mut-fwd, 50-TAG AGG
GCA TGG GTC GAT GTG GGT CGA TTC TGA
AC-30; site2-mut1-fwd, 50-GGA TT GGA TTG AGG
TGG ATT TGG TTT CC-30; site2-mut2-fwd, 50-GGA
TCA TGT TGA GGC ATG TTT GGT TTC C-30; and
the respective reverse primers.
TAp63g mutants were created by PCR-based targeted
mutagenesis using the QuikChange (Stratagene, La Jolla,
CA, USA) according to the manufacturer’s protocol on
the basis of TAp63g-pcDNA3.1/HisC (44) employing the
primers TAp63g-K193E-fwd, 50-GCC ATG CCT GTC
TAC GAA AAA GCT GAG CAC GTC AC-30; TAp63g-
K194E-fwd, 50-CAT GCC TGT CTA CAA AGA AGC
TGA GCA CGT CAC GG-30; TAp63g-R204W-fwd
50-GGA GGT GGT GAA GTG GTG CCC CAA CCA
TG-30; TAp63g-R279H-fwd, 50-GTT GTG TTG GAG
GGA TGA ACC ACC GTC CAA TTT TAA TCA TTG-
30; TAp63g-R298Q-fwd, 50-CAA GTC CTG GGC CAA
CGC TGC TTT GAG GC-30; and the respective reverse
primers. Identity of constructs was conﬁrmed by DNA
sequencing. TAp63g-R304H was published earlier (44).
Electrophoretic mobility shiftassay(EMSA)
EMSAs were carried out as previously described (53).
TAp63g was supershifted by using the goat polyclonal
anti-p63g antibody (C-18, sc-8370, Santa Cruz
Biotechnology) whereas p53 was shifted by adding a
monoclonal mouse anti-p53 antibody (pAb421, SA-293,
Biomol, Hamburg, Germany). Probes were generated by
annealing the following oligonucleotides with respective
reverse oligonucleotides: S100A2 site2, fwd 50-GGG TGG
GAT CAG GTT GAG GCA GGT TTG GTT TCC
TT-30; S100A2 site2 mut-1 fwd, 50-GGG TGG GAT TGG
ATT GAG GTG GAT TTG GTT TCC TT-30; S100A2
site2 mut-2 fwd, 50-GGG TGG GAT CAT GTT GAG
GCA TGT TTG GTT TCC TT-30; p21 fwd, 50-GGC CAT
CAG GAA CAT GTC CCA ACA TGT TGA GCT
CT-30; mdm2 fwd, 50-GGG CGG CCG CTG GTC AAG
TTG GGA CAC GTC CGG-30.
Chromatin immunoprecipitation (ChIP) assays
ChIPs were carried out guided by a published procedure
(54) using HepG2 cells (49) or DLD-1 colorectal
adenocarcinoma cells with p53 or TAp63g as tet-oﬀ-
regulated transgenes (44). Protein crosslinks were pre-
cipitated using 5mg of a goat polyclonal anti-p63g (C-18,
sc-8370, Santa Cruz Biotechnology) or monoclonal anti-
p53 antibody (DO-1, Calbiochem, Darmstadt, Germany).
Samples were analyzed as described earlier (52) employing
the primers IP-S100A2-site1-fwd, 50-CAG GAC AGA
ACA GGT AGA CAC TGA A-30; IP-S100A2-site1-rev,
50-CCT GCT GCT GCG TGT CC-30; IP-S100A2-site2-
fwd, 50-GGT CCA GGA TGC CCA GTC-30; and
IP-S100A2-site2-rev, 50-GAA GGA GAG CAA GGC
AGC-30.
RESULTS
InductionofS100A2expressionbymembersofthep53family
S100A2 is a TAp63g-target gene identiﬁed earlier in a
DNA-microarray screening (55). Another report had
previously shown that S100A2 can be upregulated by
p53 (20). With these two observations as a starting point,
we were interested to test how these two and some of the
other members of the p53 family control S100A2
expression and which functional implications this may
have. We had earlier established a tet-oﬀ regulated
expression system for the most relevant p63 splice variants
using the colorectal adenocarcinoma cell line DLD-1 (44).
We analyzed regulation of S100A2 comparing its mRNA
expression by real-time RT–PCR before and 9h after
induction of TAp63g, TAp63, Np63g, Np63,
TA p63g,T A  p63, TAp73 or p53 transgenes
(Figure 1A). We ﬁnd the mRNA of S100A2 upregulated
after induction of p53, TAp73a as well as TAp63g
proteins. The other p53 family proteins did not aﬀect
S100A2 expression signiﬁcantly. Overexpression of
TAp63g results in a strong increase of S100A2 mRNA
up to about 22-fold (Figure 1A). S100A2 induction by
p53 is consistent with a previous report by Tan and
coworkers (20).
More important for S100A2 function is an induction on
the protein level. Since a number of commercially
available antibodies were not of suﬃcient sensitivity, we
generated polyclonal antibodies against the full-length
human S100A2 protein. S100A2 protein was detected
from human HaCaT keratinocytes, known to express high
levels of the protein (3), and human colon cancer HCT116
cells transfected with an S100A2 expression plasmid as
controls by western analysis (Figure 1B). Employing this
antibody preparation, we tested S100A2 expression
comparing the protein level before and 9h after induction
of the respective transgene in the DLD-1-system. A clear
induction of S100A2 was observed following the induction
Nucleic Acids Research, 2008, Vol. 36, No. 9 2971of TAp63g (Figure 1B). However, no S100A2 protein was
detectable after induction of p53 despite a clear increase
in p53 protein expression. Taken together with the
observations on the mRNA level, this ﬁnding indicates
that S100A2 protein expression induced by TAp63g is
stronger than the induction by p53.
TAp63cregulates transcription ofthe S100A2 gene
After ﬁnding that increased expression of TAp63g leads
to elevated S100A2 mRNA and protein levels, we tested
if this regulation is controlled on the transcriptional
level. Initially, we used in our assays an S100A2-promoter
fragment-reporter construct which was kindly provided by
Dr Beat W. Scha ¨ fer (University of Zurich) and had been
published to be regulated by p53 (20). This construct,
designated S100A2 short (Figure 2A), was transfected
into SaOS-2 cells. Increasing amounts of p53-o rTAp63g-
expressing plasmids were cotransfected. As controls, their
DNA binding-deﬁcient mutants were also assayed. Wild-
type TAp63g was able to activate the promoter fragment
about 16-fold (Figure 2B). Surprisingly, p53 was not able
to induce expression from the S100A2 short construct,
leaving the question unanswered why S100A2 mRNA
increases after p53 induction. Trying to explain this
discrepancy we extended the S100A2 short promoter by
a fragment of about 2kb up to the translational start
creating S100A2 long. This reporter construct includes the
untranslated exon 1 and the ﬁrst intron (Figure 2A).
Activation by p53 of this promoter results in an increase
of about 3.5-fold. Much more substantial is the activation
by TAp63g which enhances the expression of the reporter
gene about 43-fold (Figure 2C).
Furthermore, we analyzed the inﬂuence of other p63/
p73 splice variants in the same assay. We ﬁnd a strong
activation of the reporter by expressing TAp73b which
was not tested in our previous approaches. Also TAp73a,
TA p63g and TA p63a enhance transcription of S100A2
(Figure 2E). The other p53 family proteins tested only
have a minor role in transcriptional activation of the
S100A2 promoter.
In summary, p53 is able to activate transcription of
S100A2. However, p63 and p73 proteins appear to be
more potent activators of S100A2 transcription.
A novel response element mediates TAp63c-dependent
regulation of S100A2
In order to determine the responding element mediating
S100A2 transcription by strong activators like TAp63g
we created some promoter mutants in sites similar to
the p53 consensus (Supplementary Table 1). Initially the
described p53-binding element (20) designated here as
site 1 (Supplementary Table 1) was tested. In addition to
this potential p53-binding site, referred to as S100A2 site
1–30, in silico analyses revealed an additional potential
consensus in this region, denoted as S100A2 site 1–50.
Mutation of these elements results in a loss of the p53-
dependent activation whereas TAp63g is still able to
activate this promoter mutant (Figure 2C). We narrowed
down the TAp63g-responsive part of the S100A2 promo-
ter by creating and testing several deletion mutants.
A region of about 80-bp upstream from the untranslated
exon 1 was identiﬁed to be required for TAp63g-mediated
transcription (data not shown). Comparison of this
S100A2 promoter segment to the known p53-consensus
sequence revealed a potential binding element consisting
of two consecutive palindromes lacking any spacer region
(Supplementary Table 1). This element, designated site 2,
contains 4bp which are diﬀerent from the classical
p53 consensus (RRRCWWGYYY) (56). Instead of the
established core-binding element CWWG the S100A2
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Figure 1. (A) Stimulation of S100A2 mRNA expression after selective
induction of p53 family members. In RNA preparations from DLD-1
colorectal adenocarcinoma cells stably transfected with tet-oﬀ vectors
expressing members of the p53 family S100A2 mRNA levels were
measured. Relative mRNA levels were determined by real-time RT–
PCR and changes in expression are given as induction factor
comparing mRNA levels 9h after tet-oﬀ induction to levels before
induction. Averages of three experiments including standard deviations
are shown. Average CT values are denoted before (no) and after (ind)
tet-oﬀ induction. t-test was carried out to yield statistic signiﬁcance
values (  P-value40.01;  P-value40.05). GAPDH expression was
used for standardization. (B) Stimulation of S100A2 protein expression
after induction of TAp63g. S100A2 protein was analyzed by western
blot comparing expression before (n) and 9h after (i) tet-oﬀ regulated
p53 or TAp63g expression in the colorectal adenocarcinoma cell line
DLD-1. In each lane 60mg of total cell lysate was loaded. S100A2
protein was detected with polyclonal antibodies raised against full-
length human S100A2. Lysates from HCT116 cells (15mg) transfected
with an S100A2-expressing plasmid and HaCaT cells (5mg) served as
positive controls. Induction of p53 and p63 expression was analyzed by
comparison of cell lysates before (n) and after induction (i) of the
transgenes. Detection of b-actin served as a loading control.
2972 Nucleic Acids Research, 2008, Vol. 36, No. 9promoter shows the nucleotide sequence CAGG in each
half of the palindrome. Furthermore, next to the core
another 2bp are changed in the upstream palindrome in
comparison to the consensus (Supplementary Table 1).
Moreover, phylogenetical footprint analyses reveal a
strong conservation of this site within vertebrates (data
not shown), implying a possible function for this region.
To test functional importance of site 2 we mutated this
element in a way that the core of the site was destroyed
and used the resulting reporter in transient transfection
assays (Figure 2D, site 2 mut-1). Activation of S100A2
transcription by TAp63g is essentially lost upon mutation
of site 2, identifying this element as the major site for
TAp63g-dependent transcription in the S100A2 promoter
(Figure 2D). When this mutant was tested with other
proteins of the p63/p73 family, we observed that the newly
identiﬁed site 2 appears to be essential also for transacti-
vation by these other splice variants (Figure 2E, site 2
mut-1). In contrast, mutation of site 1 aﬀects transacti-
vation of the S100A2 reporter by p63/p73 family members
only to a minor extent (Figure 2E, site 1–30 mut),
emphasizing the importance of the newly identiﬁed
element 2 for mediating p63/p73-dependent regulation of
S100A2.
In another mutant, a bona ﬁde p53 consensus was
created by changing the guanine in position three to a
thymidine in the core-binding element CAGG of site 2
(Supplementary Table 1). TAp63g was able to activate this
mutant S100A2 promoter clearly. Furthermore, this
promoter construct shows a signiﬁcant induction also
after expression of p53 (Figure 2D, site 2 mut-2).
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Figure 2. A novel site in the S100A2 promoter diﬀerent from a previously recognized element mediates transcriptional activation by TAp63g.
(A) Structure of the analyzed promoter fragments of S100A2 upstream of the translational start containing previously published p53 element (site 1)
and the newly identiﬁed TAp63g-binding element (site 2). (B) The S100A2 short-reporter is activated by increasing amounts of TAp63g but not by
p53 or DNA binding-deﬁcient mutants of TAp63g or p53. In SaOS-2 cells 250ng of the S100A2 short plasmid were cotransfected with increasing
amounts starting with 2ng up to 25ng of the plasmids expressing wild-type or DNA binding-deﬁcient mutants of TAp63g or p53. All experiments
were standardized to Renilla luciferase activity expressed from cotransfected pRL-null vector. The total amount of DNA transfected was held
constant. Averages from four experiments with standard deviations are given. (C) The S100A2 long reporter is activated by TAp63g and to a lesser
extent by p53 but not by DNA binding-deﬁcient mutants of TAp63g and p53. Mutation of site 1 abrogates p53-mediated but not TAp63g-mediated
transactivation. In SaOS-2 cells, 400ng reporter plasmid containing wild-type or mutated S100A2 long were cotransfected with 25ng of the plasmids
expressing wild-type or DNA binding-deﬁcient mutants of TAp63g or p53. Standardization was done as described above. (D) Mutations of the novel
consensus element (site 2) inﬂuence TAp63g- and p53-mediated activation of the S100A2 promoter. Transfections were done as described above.
(E) Transactivation of S100A2 by several members of the p63/p73 family is mediated by the novel element 2. Plasmids expressing p63/p73 family
members or their DNA-binding deﬁcient mutants were transfected with the S100A2 long reporter construct in SaOS-2 cells. Luciferase reporter
activities from three independent experiments with standard deviations are shown.
Nucleic Acids Research, 2008, Vol. 36, No. 9 2973palindrome appears suﬃcient to alter a site preferentially
bound by p63 and p73 proteins into a functional p53
element.
Taken together, we have identiﬁed a novel promoter
element which is diﬀerent from the established p53
consensus mediating S100A2 transactivation selectively
by p63/p73 proteins.
TAp63c,but notp53, binds thenovel S100A2 promoter
element invitro
Binding of TAp63g and p53 to the novel S100A2 pro-
moter element site 2 was tested by EMSA employing
proteins translated in vitro. An established p53-consensus
element from the p21
WAF1/CIP1 promoter was used as a
positive control. Both, wild-type TAp63g and p53 gave
a speciﬁc signal for the control element. Addition of
antibodies against p53 or p63 led to a supershifted band
(Figure 3A). EMSAs yielded binding of TAp63g to the
site 2 element in the S100A2 promoter. p53 did not
show signiﬁcant binding to this site. Enhancement of p53
binding upon supplementing antibodies had been
described (57). However, even addition of antibodies did
not yield a detectable p53 binding (Figure 3A). As a
negative control, DNA binding-deﬁcient mutants of p53
or TAp63g proteins were employed.
Applying a probe representing a mutant of site 2
which does not allow TAp63g-dependent transactivation
of the reporter binds neither p63 nor p53 in an EMSA
(Figure 3B, S100A2 site 2 mut-1). However, using a
mutant-2 probe containing the restored p53 consensus
results in an enhanced binding of wild-type TAp63g.
Consistent with our data from the reporter assays we also
ﬁnd binding of p53 to this DNA fragment (Figure 3B,
S100A2 site 2 mut-2).
Furthermore, in competition experiments, S100A2 wild-
type oligonucleotide is able to attenuate the binding
of TAp63g to a probe containing the mdm2 p53-binding
site (Figure 3C S100A2 site 2). To a lesser extent, also
binding of p53 to mdm2 is reduced. Mutant S100A2
oligonucleotide (S100A2 site 2 mut-1) failed to diminish
these interactions, whereas oligonucleotides containing the
restored p53 consensus (S100A2 site 2 mut-2) prevented
binding of TAp63g or p53 to the mdm2 probe (Figure 3C).
In conclusion, we showed a sequence-speciﬁc binding of
TAp63g to a novel S100A2 promoter element in vitro,
whereas p53 was not able to bind this fragment. Changing
one base in each half of the palindrome in order to create a
classical p53 consensus sequence resulted in an enhanced
binding by TAp63g and a clear detectable interaction also
with p53.
In vivobinding of TAp63candp53 to theS100A2 promoter
To test for binding of TAp63g protein to the novel
S100A2 promoter element in vivo we carried out ChIP
analyses. Employing DLD-1 cells carrying a tet-
oﬀ-regulated system expressing TAp63g or p53 binding
to two regions of the S100A2 promoter including binding
site 1 or site 2 was tested. TAp63g and p53 were shown to
bind to the S100A2 promoter in vivo (Figure 4).
EEC syndrome-specific mutants of TAp63cfailto
transactivate S100A2
Since we found that S100A2 expression is regulated by p63
we were interested to test mutants of this protein relevant
in human syndromes for their properties. Mutations such
as R204, R279 and R304 found in EEC patients
correspond to hotspot mutations in the DNA-binding
domain of p53 observed in cancer (58). Unlike to those
mutants, p63 mutations responsible for the SHFM
phenotype such as K193 or K194 do not directly
participate in DNA binding. In contrast to people
suﬀering from EEC syndrome, SHFM patients do not
exhibit ectodermal dysplasia and facial cleftings, which are
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Figure 3. TAp63g is able to bind to the novel S100A2 promoter consensus element in vitro, whereas no binding of p53 is detectable. Wild-type or
mutant TAp63g or p53 were produced by translation in vitro and incubated with probes representing a p53 site from p21
WAF1/CIP1 promoter as
positive control or the novel site 2 from the S100A2 promoter. In some samples, speciﬁcity of detected binding was veriﬁed by adding antibody
against p63g or p53. Samples were analyzed in EMSAs. (A) Binding of TAp63g respectively p53 to the p21
WAF1/CIP1 probe or to the S100A2
promoter wild-type site 2. (B) TAp63g or p53 binding to the S100A2 promoter wild-type site 2 or two mutants, S100A2 site 2 mut-1 and S100A2
site 2 mut-2. (C) A probe carrying a p53 site from the mdm2 promoter was employed in EMSAs. Binding to the labeled probe was competed with a
100-fold excess of unlabelled DNA of wild-type or two mutants of the S100A2 site 2.
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Several syndrome-derived p63 mutants were assayed as
transcriptional activators of the S100A2 promoter: EEC
syndrome, R204W, R279H, R304A; SHFM syndrome,
K193E, K194E; ADULT syndrome, R298Q (Figure 5).
As a control, p63 mutant proteins were tested for com-
parable expression by western analysis (data not shown).
The reporter assays indicate that EEC syndrome-derived
mutants are not able to transactivate transcription of
S100A2. In contrast, p63 mutants derived from
SHFM patients even appear to enhance S100A2 reporter
activity. Mutations related to the ADULT syndrome
are still able to stimulate some S100A2 transcription
(Figure 5).
Binding of p63cprotein tothe S100A2 promoter correlates
with S100A2 expression after DNA damage
S100A2 was described as a potential tumor suppressor
(14). Therefore, we tested if regulation of S100A2
expression may be connected to DNA damage through
p63. It had been observed earlier that p63 expression can
be induced by DNA damage (59). Consistent with these
results we found enhanced expression of TAp63 mRNA
upon treatment of HepG2 hepatocellular carcinoma cells
with doxorubicin for 24 to 48 hours. Interestingly, in line
with TAp63 expression also S100A2 mRNA expression
increases (Figure 6A). Of note is that mRNA levels of
Np63 and TAp73 isoforms did not change signiﬁcantly
in this experiment (data not shown).
HepG2 cells are positive for p53 protein expression.
In addition to these cells we also tested the p53-negative
liver cell line Hep3B for p53-protein induction after DNA
damage. As expected, only in HepG2 cells p53 increases
(Figure 6B). We examined if S100A2 expression also
changes independently of p53. Also in Hep3B cells,
S100A2 mRNA expression is induced when the p53-
negative cells are treated with doxorubicin. Furthermore,
the TAp63 mRNA level increases as well. However,
TAp63 expression is not detectable in untreated cells,
hampering a correlation between TAp63 and S100A2
expression as cause and eﬀect (Figure 6C). Also in this cell
system, levels of Np63 and TAp73 mRNAs did not
change (data not shown).
We wished to correlate expression of p63 proteins with
binding to the S100A2 promoter in vivo by ChIP assays.
i n p53 i n p53 M H2Oi n p63γ in p63γ
uninduced induced induced uninduced
DLD1-p53 DLD1-TAp63γ
S100A2 site 1
S100A2 site 2
Figure 4. TAp63g is able to bind to the novel S100A2 promoter consensus element in vivo. Chromatin from DLD-1 colorectal adenocarcinoma cells
stably transfected with tet-oﬀ vectors expressing members of the p53 family were cross-linked before (uninduced) and 9h after induction (induced) of
TAp63g or p53 expression. After precipitation with antibodies against p63g or p53, the S100A2 promoter regions containing the p53 element
published earlier (site 1) or the novel element (site 2) were ampliﬁed by PCR from the precipitated DNA. Lanes are input (i), no antibody (n), water
control (H2O) and DNA ladder (M).
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Figure 5. TAp63g mutants related to SHFM, EEC and ADULT
human developmental syndromes show a functional diﬀerence in
regulating S100A2 transcription. TAp63g mutants originating from
patients with developmental syndromes SHFM, EEC or ADULT
diﬀerentially activate the S100A2 long reporter. Transfections and
analyses were done as described above.
2976 Nucleic Acids Research, 2008, Vol. 36, No. 9However, p53-independent analysis of p63g-protein bind-
ing was not detectable likely due to low endogenous
protein amounts (data not shown). Nevertheless, in
HepG2 cells we could show binding of p63g protein to
the S100A2 promoter in vivo following DNA damage.
Recruitment of p63g is not observed in untreated cells
(Figure 6D). Distinct from binding of p63g is the
recruitment of p53 to the S100A2 promoter. p53 binds
already to the promoter in cells before DNA damage
(Figure 6D) although p53 is induced only after doxo-
rubicin treatment (Figure 6B). In conclusion, binding
of endogenous p63g protein to the S100A2 promoter
matches with enhanced mRNA expression of TAp63
isoforms after doxorubicin-induced DNA damage.
DISCUSSION
In contrast to p53, mutations of p63 are not frequently
found in human cancer. Therefore, p63 is not a classical
tumor suppressor despite strong structural homologies to
p53 (60). Elucidating other possible p63 functions is
diﬃcult due to the presence of various p63 splice variants
and their divergent expression pattern. The TAp63g
protein closely resembles p53. One reason for the
similarity is its lack of an inhibitory domain present in
the a variants. TAp63g is found to be a very potent
activator of p53 target genes (33) and seems to be able to
enforce tumor suppressive mechanisms in which p53 is
involved (34).
In addition to a possible function as a tumor
suppressor, it was discovered that p63 plays a role in
development (36,40). Heterozygous p63 germ line muta-
tions cause several skin and other developmental defects in
man (39,58). These observations suggest for p63 other
transcriptional targets than for p53.
Here we identify S100A2 as a transcriptional target of
p63. Particularly the p63 variant TAp63g is rather active
in enhancing S100A2 expression. Selective expression of
TAp63g leads to a dramatic increase in mRNA amounts
(Figure 1A) and subsequently to enhanced expression of
S100A2 protein (Figure 1B). A novel binding site in the
S100A2 promoter is essential for TAp63g-mediated
activation (Figure 2). We demonstrated that TAp63g
binds to this element in a sequence-speciﬁc manner in vitro
(Figure 3). Furthermore, the recruitment of TAp63g to the
S100A2 promoter in vivo was demonstrated (Figure 4).
A recent report showed activation of S100A2 transcription
by p73a and p73b (3). Interestingly, we could show that
the newly identiﬁed p63-response element is the activating
site also for TAp73 proteins (Figure 2E). However, an
additional element relevant for part of the p73-dependent
activation in the second intron of the S100A2 gene,
as discussed by others, cannot be excluded (3). We did
not observe a strong S100A2 repression by Np63a
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Figure 6. Recruitment of p63g protein to the S100A2 promoter may
connect S100A2 expression to DNA damage. (A) TAp63g and S100A2
mRNA expression increase after DNA damage. Real-time RT–PCR
measurements of S100A2 and TAp63 mRNAs from doxorubicin-
treated HepG2 cells. Relative mRNA levels were normalized to
expression of GAPDH mRNA. Cells before treatment were employed
as control. Control levels were set to 100%. Times of doxorubicin
treatment are indicated. (B) Western blot analyses of lysates from p53-
positive HepG2 and p53-negative Hep3B cells after doxorubicin-
induced DNA damage. Controls contain samples taken before
treatment. Doxorubicin-treated samples were analyzed after 24h or
48h. Detection of b-actin served as a loading control. (C) Expression of
S100A2 mRNA correlates with an increase of TAp63 mRNA after
doxorubicin-induced DNA damage in p53-negative Hep3B cells.
Relative mRNA levels were measured by real-time RT–PCR.
Expression of GAPDH was used for normalization. S100A2 mRNA
from untreated control cells was set to 100%. In control samples no
TAp63 mRNA was detectable. Therefore, the TAp63 mRNA measure-
ment at 24h was employed as the 100% reference. (D) Chromatin
immunoprecipitation (ChIP) assays of p53 and p63g proteins binding
to the S100A2 promoter in HepG2 cells following DNA damage.
Control and doxorubicin-treated cells were prepared as described
above. Lanes are input (i), no antibody (n), p53 and p63g antibodies.
Nucleic Acids Research, 2008, Vol. 36, No. 9 2977(Figures 1 and 2E) as detected by other researchers (3).
This may be caused by diﬀerent experimental approaches.
Lapi and coworkers employed ﬁreﬂy luciferase for
measurement of reporter activity and b-galactosidase for
normalization instead of the ﬁreﬂy/Renilla-luciferase
combination used here. The diﬀerence in protein stability
between luciferase and b-galactosidase may result in
distortion of relative reporter activities. Other diﬀerences
are the use of a DNA–binding-deﬁcient mutant of
Np63a as a control instead of empty vector and
employment of distinct cell systems (3). However, Lapi
and coworkers observed under their experimental condi-
tions that TAp63a is not able to activate the S100A2
promoter which is perfectly consistent with our ﬁndings
(Figure 2E).
S100A2 is known to be a transcriptional target of
p53 (20). Consistent with this we ﬁnd an induction of
S100A2 mRNA after expression of p53, but activation
of the S100A2 promoter by p53 was substantially lower
than the increase in expression after TAp63g induction
(Figure 2). Furthermore, on the protein level S100A2
increased after TAp63g expression, whereas an equivalent
protein induction was not detectable following p53 exp-
ression (Figure 1B). These ﬁndings suggest that TAp63g is
a more potent transcriptional activator than p53 also
implying that regulation through p63 generally may be
more relevant for S100A2 function.
We demonstrated that changing one nucleotide in the
core of the newly identiﬁed binding element 2 is suﬃcient
to diﬀerentiate between binding of p53 or TAp63g
(Figures 2D and 3B). These observations are in line with
previously published results which demonstrate that p63
preferentially binds to degenerate p53 consensus elements
(42,43). This mechanism appears to be important for
diﬀerentiating functions of p63 versus p53. Furthermore,
the evolutionary conservation of the identiﬁed binding
element in S100A2 promoters from diﬀerent species (data
not shown) suggests an essential biological relevance of
the TAp63g-dependent regulation (61).
One function of p63 is the regulation of developmental
processes. Several mutations in the p63 DNA-binding
domain are responsible for a family of human syndromes
characterized by a combination of ectrodactyly, ectoder-
mal dysplasia and facial clefting (37–39,58). These
observations led us to test the inﬂuence of disease-related
p63 mutants on transcriptional activation of S100A2.
In reporter assays, we found an even stronger transcrip-
tional activation employing two TAp63g mutants derived
from SHFM patients compared to wild-type p63
(Figure 5). In contrast, three p63 mutants responsible
for the EEC syndrome had essentially lost their activation
potential on the S100A2 promoter. A TAp63g mutant
related to the ADULT syndrome yielded some residual
S100A2 activation when compared to wild-type TAp63g
(Figure 5). Interestingly, these observations correlate
with severity of the epidermal syndrome phenotype since
SHFM patients, in contrast to patients suﬀering from
EEC and ADULT syndromes, are characterized by a lack
of epidermal dysplasia (62). Therefore, it is tempting to
speculate that the ability of p63 to stimulate expression
of S100A2 plays a role in developing the phenotype
of these patients. Further research is required to establish
a stronger link.
S100A2 was identiﬁed as a potential tumor suppressor
by subtractive hybridization between normal and tumor-
derived mammary epithelial cells in man (14). Consistent
with these ﬁndings S100A2 expression is markedly down-
regulated in several tumor tissues (15–18). However, it was
shown that S100A2 expression is increased in other
tumors (21–26). It was discussed that overexpression is
an early event in tumorigenesis. Furthermore, a physical
interaction between S100A2 and p53 proteins enhances
transcriptional activity of p53 which implies antitumori-
genic properties of S100A2 (27). A possible interaction
also between p63 and S100A2 proteins has not yet been
investigated. Recently, it was demonstrated that S100A2
expression is able to diminish expression of Cox-2 protein
which provides further evidence for a tumor suppressive
function of S100A2 (28). Interestingly, in line with these
observations we showed that expression of S100A2
increases following DNA damage (Figure 6A and C).
The enhanced expression of S100A2 correlates with
binding of p63g protein to the S100A2 promoter
(Figure 6D). Generally, detection of diﬀerent p63 isoforms
on the mRNA and protein levels is diﬃcult. It is possible
to diﬀerentiate between TAp63 and Np63 mRNA
variants. On the protein level we were able to observe
p63g versus total p63 protein expression. After DNA
damage we exclusively ﬁnd an increase in the TAp63
isoforms on the mRNA level. Combining these observa-
tions with the data from the ChIP assays suggests that
TAp63g is induced after DNA damage and subsequent
binding to the S100A2 promoter mediates its regulation
(Figure 6D). Supportive of this notion is the ﬁnding that
p53-negative Hep3B cells also show an increase in
transcription of S100A2 together with enhanced expres-
sion of the TAp63 isoforms after DNA damage is
observed (Figure 6C). In conclusion, it is possible
that regulation of S100A2 transcription by TAp63g is a
supporting mechanism to complement and enhance
cellular response in preventing tumor transformation
(34). This is consistent with earlier observations implying
that TAp63g is able to substitute partially p53 function in
hepatocellular carcinomas lacking p53 expression by
transactivating the maspin tumor suppressor (55).
In summary, we show that S100A2 is a novel trans-
criptional target of the p63 splice variant TAp63g.
The regulation is mediated by a novel and strongly
conserved transcriptional element in the S100A2 pro-
moter which is bound by TAp63g but not by p53.
Transcriptional properties of p63 mutants derived from
EEC, ADULT and SHFM syndrome patients yield
evidence for a role of a TAp63g-mediated transcription
of S100A2 in developmental processes. Recruitment of
p63g proteins to the S100A2 promoter following DNA
damage correlates with enhanced expression of S100A2
and suggest a function in tumor suppression.
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